As of Q2 2024, Lykos has completed two Phase III trials for post-traumatic stress disorder (PTSD) and submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for midomafetamine (MDMA) capsules used in combination with psychological intervention. If approved, it would be the first psychedelic-assisted therapy approved for PTSD.